Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 1
1(33.3%)
Phase 2
1(33.3%)
3Total
N/A(1)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07548021Phase 1Not Yet Recruiting

Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda

Role: collaborator

NCT07408297Phase 2Completed

Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda

Role: collaborator

NCT03045809Completed

Women's Improvement of Sexual Health (WISH) Demonstration Project

Role: collaborator

NCT02459665Not ApplicableCompleted

Rwanda Vaginal Microbiota Restoration Study

Role: collaborator

All 4 trials loaded